Introducing the Spring FAST 2018 cohort: Abalone Bio, Antibiotic Adjuvant, Atropos Therapeutics, C. Light Technologies, Melio, and Valley Fever Solutions.
Entrepreneurship
Inflammatix (FAST Fall 2017), a molecular diagnostics company that is developing rapid tests that read the immune system to improve disease diagnosis, announces appointment of Oliver Liesenfeld, M.D., former CMO of Roche Molecular Diagnostics, as Chief Medical Officer | Read More
LogicInk (FAST Spring 2017) is planning on launching its temporary tattoo-like device for recording exposure to UV radiation from the sun during the second quarter of this year. | Read More
Read interview with SciBac’s (FAST Fall 2016) CEO, Chief Science Officer and Co-Founder, Jeanette Mucha, who is designing live biotherapeutics to treat and prevent antibiotic resistant disease in the microbiome. | Read More
Eidos Therapeutics (FAST Spring 2016) presented at the JP Morgan Healthcare Conference on developing AG10, a novel small molecule therapeutic for treatment of transthyretin amyloidosis. | Read More
Ligandal (FAST Spring 2016) unveils nanotech delivery for genetic therapies: What Good Would Amazon Be Without the Shipping? | Read More
GigaGen (FAST Spring 2015) receives NIH grant to develop production technology for recombinant intravenous immunoglobulin. | Read More
GigaGen also announced moving into new office space in South San Francisco to accommodate the company’s expanding research and development activities for 2018 and beyond. | Read More
The FAST Advisory Program provides select entrepreneurs with intensive team review and coaching to perfect their business model, product development plans, and to build a compelling commercialization strategy. Experienced entrepreneurs, product and business experts (which may include clinical development, regulatory, reimbursement and business development specialists) will advise selected Fellows during a ten-to-twelve week program, culminating in a Final FAST Showcase to a broad audience that includes potential investors and partners.
Deadline to Apply for Biotech/Biopharma track of Life Science Pitch Summits, UCSF Mission Bay Apply Here
2/22
“Destroyer of Obstacles”: Going from Startup to a Commercial Organization, UCSF Mission Bay, San Francisco Register Here
2/22
Build an Amazing Diagnostics, Tools or Drug Discovery Company, UCSF Mission Bay, San Francisco Register Here
2/26
Deadline to apply for Resource Allocation Program – Catalyst Awards for the Development of Therapeutics, Diagnostics, Devices, and Digital Health More Info
2/27
Call for Entries: Boehringer Ingelheim’s San Diego Innovation Prize for young life-science companies and bio-entrepreneurs More Info
2/28
Understanding Drug Pricing, South San Francisco Register Here
2/28
GDPR for Academic Medical Centers and Life Science Companies Webinar Register Here
3/1
Sherry Parker, WuXi AppTec: “The Changing Landsape of Medtech Regulation” UCSF, Mission Bay, San Francisco Register Here
3/1
Fireside Chat with Tom Siebel: AI and IoT at Industrial Scale, Santa Clara Register Here
3/2
Deadline to apply for AbbVie and MBC BioLabs 2018 AbbVie Golden Ticket. The AbbVie Golden Ticket provides a year’s use of a lab bench and core facilities at MBC BioLabs' San Francisco or San Carlos site, as well as opportunities to engage with AbbVie scientific and business leaders. It will be awarded to an early stage company developing novel, transformational therapies for autoimmune, oncology, or neurodegenerative disease. To apply, please email your non-confidential company presentation to GoldenTicket@abbvie.com.
3/8
Women Who Lead in Life Sciences, San Francisco, CA Register Here
3/8
Entrepreneur Lessons Learned: Eric Stone, Velano Vascular, UCSF Mission Bay Register Here
3/13-16
Joint Genome Institute Genomics of Energy & Environment Meeting Register Here
3/15
MedTech Innovator 2018: JLABS Pitch Event, JLabs, South San Francisco Register Here
3/29
Meet with Frazier Healthcare Partners, JLabs, South San Francisco Register Here
3/29
Bio on the Bay with CLSA, San Francisco Register Here
4/10
Meet with Illumina Accelerator and Illumina Ventures, JLabs, South San Francisco Register Here
Meet with Pappas Capital, JLabs, South San Francisco Register Here
6/20
5th Annual Rosenman Symposium, UCSF Mission Bay Register Here
CARB-X
CARB-X is seeking to partner with additional accelerators to expand support for its growing early development antibacterial pipeline. | Read More
Powered by CARB-X company, Vedanta Biosciences was granted four new US patents expanding coverage for compositions and methods of use for therapeutics based in microbiome-derived bacterial consortia. | Read More See a recent profile of Vedanta’s CEO
Powered by CARB-X company, VenatoRx received an award for up to $16 million from the Defense Threat Reduction Agency (DTRA) to support preclinical development of a novel, first-in-class antibiotic for biodefense applications. | Read More
Powered by CARB-X company, Antabio announced the appointment of four biotech executives to the management team. | Read More
Powered by CARB-X company, Spero Therapeutics appoints David Melnick as Chief Medical Officer to oversee clinical development and regulatory strategy. | Read More
Powered by CARB-X company, Tetraphase Pharmaceuticals promotes Larry Tsai, VP Clinical Development to Chief Medical Officer to move forward with new drug application for IV eravacycline. | Read More
Powered by CARB-X company, Entasis Therapeutics ranked highest among biotech companies in their contributions toward stewardship. | Read More
Powered by CARB-X company, BugWorks’ is using advanced mathematical models and algorithms to design appropriate chemical compounds to attack resistant bacteria. | Read Moreabout their approach and other ‘Big Data’ techniques for antibiotic discovery.
Other AMR News
New article just published in The Lancet Infectious Disease: Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. | Read More
Debut of FDA Susceptibility Test Interpretive Criteria (STIC) website. | Read More
Research project DRIVE-AB (Driving Re-investment in research and development for antibiotics and advocating their responsible use) determined that a market entry reward of $1 billion per antibiotic globally could increase the number of new antibiotics entering the market in the next 30 years. | Read More
The Pew Charitable Trusts’ antibiotic resistance project and the World Health Organization (WHO) have both released new analyses of the pipeline of products in clinical development with potential to treat or prevent serious drug-resistant bacterial infections. | Read More
Wellcome Trust is bringing together a new international expert group, SEDRIC (Surveillance and Epidemiology of Drug-Resistant Infections Consortium) to “help transform the way countries are able to track, share and analyse information about the rise and spread of infections.” | Read More
Scientists at the University of Queensland in Australia are attacking antibiotic-resistant bacteria by re-engineering vancomycin to make “supercharged” antibiotics, called vancapticins. | Read More
Locus Biosciences and IDbyDNAannounce partnership to develop a companion diagnostic test for pseudomonas aeruginosa infection. | Read More
St. Louis startup, BacterioScan received NIH grant to develop laser technology to rapidly test for urinary tract infectious. | Read More
Melinta Therapeuticsannounced the U.S. launch of Baxdela, an antibiotic for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. | Read More
Paratek Pharmaceuticals announced completion of submission of two NDAs to the FDA for once-daily oral and IV formulations of broad-spectrum investigational antibiotic, omadacycline. | Read More
FDA cites progress in facilitating the development of new antibacterial drugs, however, additional efforts are needed. | Read More
SAB Biotherapeutics announced its first-in-human trial for new immunotherapy approach showing efficacy in antibiotic-resistant bacteria. | Read More
Regular surfers and bodyboarders are three times more likely to have antibiotic resistant E.coli in their guts than non-surfers. | Read More
The Combating Antibiotic Resistant Bacteria Accelerator (CARB-X) is the world’s largest public-private partnership focused on tackling AMR, bringing together leaders in industry, philanthropy, government and academia to rejuvenate the antimicrobial pipeline. The CARB-X consortium includes BARDA and NIAID (U.S. Department of Health and Human Services), the AMR Centre, the Wellcome Trust, the California Life Sciences Institute (CLSI), MassBio, the Broad Institute, Boston University School of Law and RTI International (RTI).
CLSI helps build the next generation of life science professionals by bringing industry and institutions of learning together to improve STEM education in California and to inspire and develop life science careers. CLSI also works to ensure that the current and anticipated talent needs of the industry are met, and that the workforce pipeline for the industry remains strong.
Upcoming Events
2/15
MBA Information Session for Biotech Professionals More Info
2/20
Young Women in BIO (YWIB) Speed Networking Event with Female Students, Wallenberg High School, San Francisco More Info
3/13
MBA Information Session for Biotech Professionals More Info
3/15
Deadline to submit application for BioGENEius (April 26, 2018), South San Francisco, CA More Info
About the California Life Sciences Institute
The California Life Sciences Institute (CLSI) supports the foundations of innovation that have made California home to the world's most prominent life sciences ecosystem. With a focus on the San Francisco Bay Area, CLSI's mission is to maintain California's leadership in life sciences innovation through support of entrepreneurship, education and career development. CLSI serves as an accelerator for the international CARB-X program devoted to combatting anti-microbial resistance. CLSI is an affiliate of the California Life Sciences Association (CLSA), which represents California's leading life sciences organization. The California Life Sciences Institute is a non-profit 501(c)(3), and was established in 1990 as the BayBio Institute. Learn more at http://califesciencesinstitute.org.
California Life Sciences Institute 9191 Towne Centre Dr Suite 450 San Diego CA 92122 USA
You received this email because you are subscribed to Marketing Information from California Life Sciences Association .
Update your email preferences to choose the types of emails you receive.